Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2513923 | 0.82 | CYP2D6 (0.34) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL3958639 | 0.80 | KDM4E (0.33) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL17344111 | 0.80 | CYP2C9 (0.43) | KDM4EMAPTALDH1A1MAPK1CA12 | |
| SCHEMBL504372 | 0.80 | PAOX (0.33) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL11255941 | 0.79 | PLA2G2C (0.42) | RECQLALDH1A1PLA2G2CMAPK1CA1 | |
| SCHEMBL182014 | 0.79 | TGFBR1 (0.47) | — | |
| SCHEMBL28901847 | 0.78 | SMN1; SMN2 (0.36) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL29105385 | 0.78 | KDM4E (0.32) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL7026251 | 0.78 | CNR2 (0.34) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL347088 | 0.78 | KDM4E (0.32) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-21 | — | — | US | claimed |
| US-20230031479-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | US | claimed |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-10 | — | — | US | claimed |
| US-20200179374-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-11 | — | — | US | claimed |
| EP-3468545-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | President and Fellows of Harvard College (US) | 2019-04-17 | — | — | EP | claimed |
| US-9956189-B2 | Material and methods for treating developmental disorders including comorbid and idiopathic autism | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-05-01 | — | — | US | claimed |
| WO-2017214442-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-14 | — | — | WO | claimed |
| US-20160303057-A1 | MATERIAL AND METHODS FOR TREATING DEVELOPMENTAL DISORDERS INCLUDING COMORBID AND IDIOPATHIC AUTISM | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | US | claimed |
| US-9463172-B2 | Material and methods for treating developmental disorders including comorbid and idiopathic autism | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2016-10-11 | — | — | US | claimed |
| EP-2395990-B1 | Material and methods for treating developmental disorders including comorbid and idiopathic autism | UNIV INDIANA RES & TECH CORP (US) | 2015-01-07 | — | — | EP | claimed |
| US-20120016036-A1 | MATERIAL AND METHODS FOR TREATING DEVELOPMENTAL DISORDERS INCLUDING COMORBID AND IDIOPATHIC AUTISM | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2012-01-19 | — | — | US | claimed |
| WO-2010093859-A1 | MATERIAL AND METHODS FOR TREATING DEVELOPMENTAL DISORDERS INCLUDING COMORBID AND IDIOPATHIC AUTISM | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-08-19 | — | — | WO | claimed |
| US-20250186429-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-06-12 | — | — | US | disclosed |
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-21 | — | — | US | disclosed |
| US-12042566-B2 | Formulations of homotaurines and salts thereof | CONFLUENCE PHARMACEUTICALS, LLC (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20020119912-A1 | Treatment of posttraumatic strees disorder, obsessive-compulsive disorder and related neuropsychiatric disorders | SYNCHRONEURON INC. | 2002-08-29 | — | — | US | disclosed |
| US-6391922-B1 | ADMINISTERING NEUROTRANSMITTER | SYNCHRONEURON, LLC | 2002-05-21 | — | — | US | disclosed |
| EP-1162960-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POSTTRAUMATIC STRESS DISORDER | Synchroneuron, LLC (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056301-A2 | TREATMENT OF POSTTRAUMATIC STRESS DISORDER, OBSESSIVE-COMPULSIVE DISORDER AND RELATED NEUROPSYCHIATRIC DISORDERS | SYNCHRONEURON, LLC (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186429-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | KDM4E 4124/4885MAPT 613/4885THRB 290/4885 |
| US-20120016036-A1 | MATERIAL AND METHODS FOR TREATING DEVELOPMENTAL DISORDERS INCLUDING COMORBID AND IDIOPATHIC AUTISM | GRIN3A, GRIK3, INA | KDM4E 3216/4885MAPT 624/4885THRB 3807/4885 |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | MECP2, GABBR1, GABBR2 | KDM4E 4124/4885MAPT 613/4885THRB 290/4885 |
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | MECP2, GABBR1, GABBR2 | KDM4E 4124/4885MAPT 613/4885THRB 290/4885 |
| US-20160303057-A1 | MATERIAL AND METHODS FOR TREATING DEVELOPMENTAL DISORDERS INCLUDING COMORBID AND IDIOPATHIC AUTISM | GRIN3A, GRIK3, INA | KDM4E 3216/4885MAPT 624/4885THRB 3807/4885 |
| US-20200179374-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | KDM4E 4124/4885MAPT 613/4885THRB 290/4885 |
| US-20230031479-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | KDM4E 4124/4885MAPT 613/4885THRB 290/4885 |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC5A7, SLC19A1, SLC43A1 | KDM4E 2401/4885MAPT 2642/4885THRB 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.